Healthcare >> CEO Interviews >> February 7, 2005

Robert Ashley – Amplimed

ROBERT A. ASHLEY is Chairman, CEO and President .of AmpliMed, his career in the pharmaceutical industry extends over 24 years, and encompasses both large and small companies. After graduating with a Masters Degree in Biochemistry from Oxford University, Mr. Ashley joined Amersham International plc, where he served in numerous roles in manufacturing, development and marketing, was responsible for the launch of several new radiopharmaceutical products, and also served as UK Sales Manager. From there he joined Squibb Corporation as Commercial Development Manager in the Diagnostics Division, and served in several marketing and business development positions of increasing responsibility within Bristol-Myers Squibb, being responsible for launching new contrast agents in various radiological specialties with a primary emphasis on improved cancer diagnosis. In 1994 Mr. Ashley joined a venture-backed start-up company, CollaGenex Pharmaceuticals Inc., as its second full-time employee, and served as Vice President and subsequently Senior Vice President of Commercial Development as the company grew into a profitable, publicly- traded specialty pharmaceutical company with 160 employees and sales in excess of $50MM. His responsibilities during this period included research, development, regulatory, clinical, manufacturing, business development, licensing and intellectual property, along with the development of CollaGenex' business outside the United States. He was responsible for guiding CollaGenex' lead product Periostat the clinical development and regulatory process, and also for the successful relationship between the company and the National Cancer Institute for the development of the cancer drug, Metastat(r) . He is the author of several scientific papers and is the inventor of several granted and pending patents. Profile
TWST: What is AmpliMed?

Mr. Ashley: AmpliMed Corporation is a clinical stage pharmaceutical

company that is exclusively focused on the rapid and efficient

development of novel drugs for the